Introduction {#S0001}
============

Prostate cancer (PCa) is the third most frequently diagnosed human malignant tumor and the seventh leading cause of cancer-related deaths worldwide.[@CIT0001] The morbidity rate of PCa has increased rapidly in China over the past decade.[@CIT0002] It is also the most common male tumor in Europe and USA, with an morbidity of 214 cases per 1000 men.[@CIT0003]--[@CIT0005] Currently, the first-line treatment options for PCa are surgical resection, chemotherapy (including targeted therapy), radiotherapy, and hormone therapy.[@CIT0006] Although great progress has been made in the diagnosis and treatment of PCa in recent years, the long-term clinical outcomes of patients with PCa are still unsatisfactory.[@CIT0007],[@CIT0008] Several risk factors, including age, genetic factors, androgen dependence, sex hormones, environmental factors, and diet, have been implicated in PCa pathogenesis.[@CIT0009],[@CIT0010] The activation of oncogenes and the suppression of tumor-suppressing genes also perform major contributions to PCa oncogenesis.[@CIT0011],[@CIT0012] However, the mechanisms involved in the development and progression of PCa are not well understood. Therefore, additional data complementing the existing knowledge about the molecular mechanisms underlying the initiation and progression of PCa are urgently needed and may be useful for developing new therapies for treating this malignant tumor.

MicroRNAs (miRNAs), a group of noncoding short RNAs of 18--22 nucleotides, can selectively interact with the 3′ untranslated region (3′-UTRs) of their target mRNAs, thus promoting their degradation and inducing translation suppression.[@CIT0013] To date, \>2000 miRNA genes have been confirmed in the human genome and are estimated to modulate approximately one-third of all human protein-coding genes.[@CIT0014] All the factors involved in physiological and pathological processes, such as cell survival, development, differentiation, metabolism, and carcinogenesis, are regulated by miRNAs.[@CIT0015],[@CIT0016] A plenty of studies showed that miRNAs perform crucial roles in the control of anti-cancer immune response through the regulation of immune checkpoints.[@CIT0017]--[@CIT0019] In terms of cancer, miRNAs play either a tumor-suppressive or tumor-promoting role depending on the characteristics of their target genes, and affect a number of malignant characteristics.[@CIT0020]--[@CIT0022] Aberrant miRNA expression has been frequently identified in PCa and demonstrated to be closely associated with prostate carcinogenesis, including PCa progression.[@CIT0023]--[@CIT0025] In addition, miRNAs are regarded as perfect candidates for identifying tumor diagnosis and prognosis biomarkers.[@CIT0026],[@CIT0027] Therefore, an in-depth exploration of PCa-related miRNAs may offer novel insights into the molecular pathways underlying PCa progression and facilitate the identification of novel targets for anticancer therapy.

At present, serum prostate specific antigen (PSA) is the most commonly used diagnosis biomarker for PCa, yet it still has limitation such as low specificity.[@CIT0021],[@CIT0028] Accordingly, the interest in miRNA research is due to the fact that PSA shows several limitations and an early diagnosis especially in the high risk is needed. The crucial roles of miR-939 have been demonstrated in several types of human cancer, including colorectal,[@CIT0029] gastric,[@CIT0030] and ovarian cancer.[@CIT0031] However, the expression profile and precise roles of miR-939 in PCa remain unclear. Hence, this study investigated miR-939 expression in PCa tissues and cell lines and explored the effect of miR-939 on the malignant phenotype of PCa cells in vitro and in vivo. Moreover, the mechanisms underlying miR-939's action on PCa progression were explored at the molecular level. Our results may offer opportunities for identifying effective diagnosis biomarker and promising therapeutic strategies to inhibit PCa progression.

Materials and Methods {#S0002}
=====================

Patients and Tissue Samples {#S0002-S2001}
---------------------------

A total of 58 pairs of PCa tissue samples and their corresponding adjacent normal tissues were collected from patients who received surgical treatment at The Third Affiliated Hospital of Sun Yat-Sen University. None of the patients had been treated with chemotherapy, radiotherapy, or other anticancer therapies before surgery. The status of lymphatic metastasis was determined by the pathological examination. All tissue specimens were stored in liquid nitrogen for subsequent total RNA or protein isolation. All experimental steps involving the use of clinical tissues were approved by the Ethics Committee of the Tongde Hospital of Zhejiang Province and performed in accordance with the Declaration of Helsinki. In addition, written informed consent was obtained from all participating patients.

Cell Culture {#S0002-S2002}
------------

Human PCa cell lines (DU145, 22RV1, LNCaP, and PC3) were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The culture medium Eagle's Minimum Essential Medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used for DU145 cells. Cell lines 22RV1and LNCaP were kept in RPMI-1640 Medium (Gibco; Thermo Fisher Scientific, Inc.,), while Ham's F-12 medium (Gibco; Thermo Fisher Scientific, Inc.,) was used for PC3 cells. All above basal medium was supplemented with 10% fetal bovine serum (FBS) and 1% of penicillin/streptomycin (all from Gibco; Thermo Fisher Scientific,).

A normal prostatic epithelial cell line (RWPE-1; Chinese Academy of Sciences) was cultured in Keratinocyte Serum Free Medium (Gibco; Thermo Fisher Scientific,) containing 10% FBS. All cell lines were cultured at 37°C in a humidified atmosphere comprising 5% CO~2~.

Oligonucleotides, Plasmids, and Cell Transfection {#S0002-S2003}
-------------------------------------------------

miR-939 agomir (agomir-939), negative control (NC) agomir (agomir-NC), the hepatoma-derived growth factor (HDGF)-overexpressing plasmid pcDNA3.1-HDGF lacking its 3′-UTR (pc-HDGF), and an empty pcDNA3.1 vector were chemically synthesized by GenePharma (Shanghai, China). Small interfering RNA (siRNA) inhibiting the expression of HDGF (si-HDGF) and NC siRNA (si-NC) were acquired from RiboBio Co., Ltd. (Guangzhou, China). For transfection, the cells were seeded in 6-well plates. The aforementioned nucleic acids were transfected into the cells using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol.

Reverse Transcription--Quantitative Polymerase Chain Reaction (RT--qPCR) {#S0002-S2004}
------------------------------------------------------------------------

Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen GmbH, Hilden, Germany) and then reverse transcribed using the miScript Reverse Transcription Kit (Qiagen GmbH). After complementary DNA (cDNA) was produced, qPCR was conducted to determine miR-939 expression using the miScript SYBR Green PCR Kit (Qiagen GmbH). To quantify *HDGF* mRNA expression, cDNA was synthesized from total RNA with the PrimeScript RT Reagent Kit (Takara Biotechnology Co., Ltd., Dalian, China). This cDNA was then subjected to qPCR with SYBR Premix Ex Taq™ (Takara Biotechnology Co., Ltd.). Small nuclear RNA U6 and *GAPDH* served as the internal references for miR-939 and *HDGF* mRNA, respectively. The relative gene expression was analyzed using the 2^−∆∆Cq^ method.

Cell Counting Kit-8 (CCK-8) and Colony Formation Assays {#S0002-S2005}
-------------------------------------------------------

Transfected cells were harvested at 24 h posttransfection and used for evaluating cell proliferation. For the CCK-8 assay, cells were seeded in 96-well plates at a density of 2 × 10^3^ cells per well. At 0, 24, 48, and 72 h after seeding, the CCK-8 assay was conducted by adding 10 μL of the CCK-8 solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) into each well. Following 2 h of incubation at 37°C, the absorbance was measured at 490 nm using a SUNRISE Microplate Reader (Tecan Group, Ltd., Mannedorf, Switzerland).

For the colony formation assay, 1 × 10^3^ transfected cells per well were seeded in 6-well plates. Next, the cells were incubated at 37°C in the humidified chamber comprising 5% CO~2~ for 2 weeks. On day 15, the cells were fixed in 4% polyformaldehyde (Sigma‐Aldrich, St. Louis, MO) and rinsed twice with phosphate-buffered saline (PBS). The colonies were then counted (≥50 cells) under a light microscope (Olympus Corporation, Tokyo, Japan).

Cell Apoptosis Quantitation by Flow Cytometry {#S0002-S2006}
---------------------------------------------

After 48 h of transfection, the cells were detached using 0.25% trypsin (Gibco; Thermo Fisher Scientific, Inc.), centrifuged, and washed twice with ice-cold PBS. The proportion of apoptotic cells was determined using the Annexin V/Fluorescein Isothiocyanate (FITC) Apoptosis Detection Kit (BioLegend, Inc., San Diego, CA, USA). In particular, transfected cells were resuspended in 100 µL of 1× binding buffer. The buffer was then combined with 5 µL of annexin V/FITC and 5 µL of propidium iodide (PI). After 30 min of incubation at room temperature in the dark, the proportion of apoptotic cells was measured in the samples using flow cytometric assays (BD Biosciences, Franklin Lakes, NJ, USA).

Transwell Assay {#S0002-S2007}
---------------

A total of 100 µL of FBS-free DMEM comprising 5 × 10^4^ cells was added into the upper compartments of transwell inserts that were precoated with Matrigel (both from BD Biosciences), followed by the addition of 600 µL of DMEM comprising 20% FBS into the lower compartments. After culturing for 24 h at 37°C in 5% CO~2~, the Matrigel and noninvaded cells remaining on the upper surface of the transwell inserts were gently removed with a cotton swab. The invaded cells were fixed in 4% paraformaldehyde, stained with 0.1% crystal violet, and rinsed thrice with PBS. After the random selection of five visual fields (200 × magnification), images of the invaded cells were captured under a light microscope, and the average value was regarded as the number of invaded cells. The migratory capacity of the cells was assessed using an assay similar to the above-mentioned experimental procedure, but the transwell inserts were not coated with Matrigel.

Tumor Xenograft Model {#S0002-S2008}
---------------------

The experimental procedures involving mice were approved by the Animal Ethics Committee of the Third Affiliated Hospital of Sun Yat-Sen University and conducted in compliance with the 2009 Animal Protection Law of the People's Republic of China. Male BALB/c nude mice aged 4--6 month and weighing 18--22 g were obtained from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (Beijing, China). PCa cells (DU145) transfected with agomir-939 or agomir-NC were subcutaneously inoculated into the flank of nude mice. The width and length of tumor xenografts were measured at 2-day intervals. Four weeks after the injection, all nude mice were euthanized, and the tumor xenografts were obtained for subsequent analysis. Tumor volume was calculated using the following formula: 0.5 × width^2^ (cm^2^) × length (cm).

Online Bioinformatics Tools {#S0002-S2009}
---------------------------

The targets of miR-939 were searched using microRNA.org ([<http://www.microrna.org/microrna/home.do>]{.ul}) and TargetScan 7.1 ([<http://www.targetscan.org/>]{.ul}).

Luciferase Reporter Assay {#S0002-S2010}
-------------------------

The fragments of the *HDGF* 3′‐UTR comprising wild-type (wt) or mutant (mut) miR-939-binding sites were designed and amplified by GenePharma. The wt and mut fragments were inserted into the psiCHECK‐2™ luciferase plasmid (Promega Corporation, Madison, WI, USA) to generate psiCHECK--HDGF-3′-UTR-wt and psiCHECK--HDGF-3′-UTR-mut reporter plasmids, respectively. Cells were seeded in 24-well plates at 60% confluence. Cotransfection of either psiCHECK--HDGF-3′-UTR-wt or psiCHECK--HDGF-3′-UTR-mut and either agomir-939 or agomir-NC was performed using Lipofectamine™ 2000, according to the manufacturer's instructions. After cultivation for 48 h, the luciferase activity was evaluated using the Dual Luciferase Reporter Assay Kit (Promega).

Western Blotting {#S0002-S2011}
----------------

Total protein was extracted with radioimmunoprecipitation assay (RIPA) buffer (Wlaterson, Barcelona, Spain). Total protein concentration was determined with the Bicinchoninic Acid (BCA) Protein Assay Kit (Pierce; Thermo Fisher Scientific, Inc.). The same amounts of protein were subjected to sodium dodecyl sulfate--polyacrylamide gel electrophoresis in 10% polyacrylamide gels and then transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). After blocking with 5% fat-free milk at room temperature for 2 h, the target proteins in the membranes were probed with specific antibodies at 4°C overnight. Thereafter, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (ab6721 or ab205719; 1:5000 dilution, Abcam, Cambridge, UK) at room temperature for 2 h. The protein signals were detected using an enhanced chemiluminescence system (Pierce; Thermo Fisher Scientific, Inc.). The primary antibodies were used at a 1:1000 dilution and included a rabbit monoclonal antihuman HDGF antibody (ab128921; Abcam), rabbit monoclonal antihuman β-catenin antibody (ab32572; Abcam), mouse monoclonal antihuman phospho-(p-)β-catenin antibody (sc-57534; Santa Cruz Biotechnology, Dallas, TX, USA), rabbit monoclonal antihuman cyclin D1 antibody (ab134175; Abcam), and rabbit antihuman GAPDH antibody (sc-32233; Santa Cruz Biotechnology).

Statistical Analysis {#S0002-S2012}
--------------------

All data were expressed as means ± standard deviation and analyzed using the Student's *t*-test or one-way analysis of variance, followed by a multiple comparison test. The chi-squared test (χ^2^ test) was used to determine the association between miR-939 expression and the clinical parameters of patients with PCa. All patients were followed up 100 months, and the Kaplan--Meier method was used to construct the survival curve. Differences among the survival curves were evaluated by the Log rank test. The correlation between miR-939 and *HDGF* mRNA expression was tested using Spearman correlation analysis. P values of \<0.05 were considered statistically significant.

Results {#S0003}
=======

Low miR-939 Expression in PCa Tissues and Cell Lines Correlates with a Poor Prognosis {#S0003-S2001}
-------------------------------------------------------------------------------------

To explore miR-939's specific characteristics involved in PCa progression, its expression profile was determined in PCa tissues and their corresponding adjacent normal tissues by RT--qPCR. miR-939 expression was found to be lower in the PCa tissues than in their corresponding adjacent normal tissues ([Figure 1A](#F0001){ref-type="fig"}, P \< 0.05). Consistent with this finding, miR-939 expression was lower in all the tested PCa cell lines---DU145, 22RV1, LNCaP, and PC3---then in the prostatic epithelial cell line RWPE-1 ([Figure 1B](#F0001){ref-type="fig"}, P \< 0.05).Figure 1Low miR-939 expression in PCa tissues and cell lines. (**A**) RT--qPCR revealed the expression levels of miR-939 in PCa tissues and their corresponding adjacent normal tissues (n = 58). \*P \< 0.05 compared with the corresponding adjacent normal tissues. (**B**) RT--qPCR revealed the miR-939 expression in four PCa cell lines (DU145, 22RV1, LNCaP, and PC3). The prostatic epithelial cell line RWPE-1 served as the control. \*P \< 0.05 compared with RWPE-1. (**C**) The relationship between miR-939 expression and overall survival among patients with PCa evaluated with Kaplan--Meier analysis. P = 0.033.

To determine the clinical value of miR-939 in PCa, all patients with PCa were classified into low miR-939 expression (n = 29) and high miR-939 expression (n = 29) groups. The median value of miR-939 expression among the PCa tissues was defined as the threshold. Then, the correlation between miR-939 expression and the clinical parameters of the patients with PCa was analyzed by the χ^2^ test. We found that low miR-939 expression was notably correlated with tumor stage (P = 0.033) and lymphatic metastasis (P = 0.028), whereas no significant correlation was observed with age, preoperative prostate-specific antigen level, Gleason score, or distant metastasis ([Table 1](#T0001){ref-type="table"}). In addition, patients with PCa exhibiting low miR-939 expression had a worse overall survival than those with high miR-939 expression ([Figure 1C](#F0001){ref-type="fig"}, P = 0.033). These results suggest the strong involvement of miR-939 PCa oncogenicity.Table 1miR-939 Expression Level (High vs Low) in Correlation with Clinicopathological Characteristics Among Patients with PCa (n=58)CharacteristicsmiR-939P valueLowHighAge (years)0.787 \<651210 ≥651719Preoperative PSA (ng/mL)0.790 \<101113 ≥101816Gleason Score0.182 \<7915 ≥72014Tumor Stage0.033\* T1--T2817 T3--T42112Lymphatic M﻿etastasis0.028\* Negative615 Positive2314Distant Metastasis0.100 Negative1522 Positive147[^2]

miR-939 Overexpression Inhibits PCa Cell Proliferation and Colony Formation, Facilitates Apoptosis, and Attenuates Cell Migration and Invasion in vitro {#S0003-S2002}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Because of the low miR-939 expression in PCa tissues and cell lines, gain-of-function assays were conducted to evaluate the role of miR-939 in PCa progression via transfection of agomir-939 into DU145 and PC3 cell lines. RT--qPCR findings revealed that compared with the transfection of agomir-NC, the transfection of agomir-939 into DU145 and PC3 cells markedly increased the miR-939 expression ([Figure 2A](#F0002){ref-type="fig"}, P \< 0.05). The effects of miR-939 overexpression on PCa cell proliferation were examined by CCK-8 and colony formation assays, whereas the effects of miR-939 overexpression on the apoptosis of PCa cell apoptosis were examined using flow cytometric assays. The results revealed that exogenous miR-939 expression suppressed cell proliferation ([Figure 2B](#F0002){ref-type="fig"}, P \< 0.05) and colony formation ([Figure 2C](#F0002){ref-type="fig"}, P \< 0.05) and induced apoptosis ([Figure 2D](#F0002){ref-type="fig"}, P \< 0.05) of DU145 and PC3 cells. Furthermore, transwell assays suggested that compared with agomir-NC-transfected cells, the miR-939-overexpressing DU145 and PC3 cells exhibited impaired migratory ([Figure 2E](#F0002){ref-type="fig"}, P \< 0.05) and invasive ([Figure 2F](#F0002){ref-type="fig"}, P \< 0.05) abilities. Taken together, these results suggested that miR-939 overexpression decreased PCa cell growth and metastasis in vitro.Figure 2miR-939 inhibits the growth and metastasis of DU145 and PC3 cells in vitro. (**A**) RT--qPCR revealed the miR-939 expression in DU145 and PC3 cells transfected with either agomir-939 or agomir-NC. \*P \< 0.05 compared with the agomir-NC-transfected cells. (**B, C**) CCK-8 and colony formation assays demonstrated the suppression of DU145 and PC3 cell proliferative and colony formation abilities by miR-939 overexpression. \*P \< 0.05 compared with the agomir-NC-transfected cells. (**D**) The stimulatory effect of miR‐939 overexpression on DU145 and PC3 cell apoptosis was evaluated by flow cytometric assays. \*P \< 0.05 compared with the agomir-NC-transfected cells. (**E, F**) Transwell assays were conducted to assess the migration and invasiveness of DU145 and PC3 cells after miR-939 overexpression. \*P \< 0.05 compared with the agomir-NC-transfected cells.

*HDGF* Is a Direct Target Gene of miR-939 in PCa {#S0003-S2003}
------------------------------------------------

To elucidate the molecular mechanisms underlying the biological functions of miR-939 in PCa, we conducted bioinformatics analysis to predict the potential targets of miR-939 and found a highly conserved binding site for miR-939 in the 3′-UTR of *HDGF* mRNA ([Figure 3A](#F0003){ref-type="fig"}). We next measured HDGF expression in miR-939-overexpressing DU145 and PC3 cells to determine whether miR-939 regulates endogenous HDGF expression. Following exogenous miR-939 overexpression, the mRNA ([Figure 3B](#F0003){ref-type="fig"}, P \< 0.05) and protein ([Figure 3C](#F0003){ref-type="fig"}, P \< 0.05) levels of HDGF were significantly decreased in DU145 and PC3 cells. We also performed a luciferase reporter assay to further test our hypothesis that HDGF is a direct target of miR-939 and found that miR-939 upregulation significantly decreased the luciferase activity generated by the plasmid harboring the wt miR-939-binding site (P \< 0.05). Conversely, mutation of the binding sequences in the 3′-UTR of *HDGF* abrogated the suppression of luciferase activity induced by agomir-939 introduction ([Figure 3D](#F0003){ref-type="fig"}). These results suggested a direct correlation between miR-939 and the 3′-UTR of *HDGF*. Taken together, the above results validated *HDGF* as a direct target of miR-939 in PCa.Figure 3Validation of *HDGF* as a direct target gene of miR-939 in PCa. (**A**) Sequence alignment of miR-939 and its predicted binding sites in the 3′-UTR of *HDGF* mRNA. The mutant binding sequences are also shown. (**B, C**) The mRNA and protein levels of *HDGF* in DU145 and PC3 cells were measured in response to agomir-939 or agomir-NC transfection in cells. \*P \< 0.05 compared with the agomir-NC-transfected cells. (**D**) Luciferase reporter assay was conducted 48 h after cotransfection of DU145 and PC3 cells with either psiCHECK--HDGF-3′-UTR-wt or psiCHECK--HDGF-3′-UTR-mut and either agomir-939 or agomir-NC to determine the interaction between miR-939 and the 3′-UTR of *HDGF* mRNA in PCa. \*P \< 0.05 compared with the agomir-NC-transfected cells.

HDGF Expression Is Inversely Correlated with miR-939 Expression in PCa Tissues {#S0003-S2004}
------------------------------------------------------------------------------

Next, we measured HDGF expression in PCa tissues and their corresponding adjacent normal tissues by RT--qPCR. The expression of *HDGF* mRNA was significantly higher in PCa tissues than in their corresponding adjacent normal tissues ([Figure 4A](#F0004){ref-type="fig"}, P \< 0.05). Moreover, there was an inverse correlation between the expression of miR-939 and *HDGF* mRNA in PCa tissues, as revealed by Spearman correlation analysis ([Figure 4B](#F0004){ref-type="fig"}; R^2^ = 0.3605, P \< 0.0001). Furthermore, the mRNA ([Figure 4C](#F0004){ref-type="fig"}, P \< 0.05) and protein ([Figure 4D](#F0004){ref-type="fig"}, P \< 0.05) levels of HDGF were lower in the high miR-939 expression group than in the low miR-939 expression group.Figure 4HDGF and miR-939 expression levels were inversely correlated in PCa tissues. (**A**) *HDGF* mRNA expression was analyzed in PCa tissues and their corresponding adjacent normal tissue samples (n = 58) by RT--qPCR. \*P \< 0.05 compared with the corresponding adjacent normal tissues. (**B**) Spearman correlation analysis indicated an inverse correlation between *HDGF* mRNA and miR-939 levels in PCa tissues. R^2^ = 0.3605, P \< 0.0001.(**C, D**) The mRNA and protein levels of *HDGF* were compared between high and low miR-939 expression groups. \*P \< 0.05 compared with the low miR-939 expression group.

Effects of HDGF Knockdown are Similar to Those of miR-939 Upregulation in PCa Cells {#S0003-S2005}
-----------------------------------------------------------------------------------

To explore the biological roles of HDGF in PCa tumorigenesis, si-HDGF and si-NC were chemically synthesized and introduced into DU145 and PC3 cells. The transfection of si-HDGF clearly downregulated HDGF in DU145 and PC3 cells, as evidenced by Western blotting ([Figure 5A](#F0005){ref-type="fig"}, P \< 0.05). Next, we examined the influence of *HDGF* silencing on cell proliferation using CCK-8 and colony formation assays and found that *HDGF* silencing strongly decreased the proliferative ([Figure 5B](#F0005){ref-type="fig"}, P \< 0.05) and colony formation ([Figure 5C](#F0005){ref-type="fig"}, P \< 0.05) abilities of DU145 and PC3 cells. In addition, HDGF knockdown markedly increased the apoptosis rate of DU145 and PC3 cells ([Figure 5D](#F0005){ref-type="fig"}, P \< 0.05). The results of the transwell assay indicated that inhibition of HDGF significantly attenuated the migration ([Figure 5E](#F0005){ref-type="fig"}, P \< 0.05) and invasiveness ([Figure 5F](#F0005){ref-type="fig"}, P \< 0.05) of DU145 and PC3 cells. Taken together, these data suggested that HDGF downregulation can have effects similar to those of miR-939 overexpression in PCa cells, thus confirming HDGF as a downstream mediator of miR-939 in PCa.Figure 5Overexpression of miR-939 and silencing of *HDGF* have similar effects on DU145 and PC3 cells. (**A**) DU145 and PC3 cells were transfected with either si-HDGF or si-NC. Western blotting was performed to determine the transfection efficiency. \*P \< 0.05 compared with the si-NC-transfected cells. (**B, C**) The proliferation and colony formation of DU145 and PC3 cells after HDGF silencing were examined by CCK-8 and colony formation assays. \*P \< 0.05 compared with the si-NC-transfected cells. (**D**) The apoptosis rates of DU145 and PC3 cells after either si-HDGF or si-NC transfection were analyzed by flow cytometric assays via PI and annexin V/FITC double staining. \*P \< 0.05 compared with the si-NC-transfected cells. (**E, F**) Transwell assays were conducted to determine the influence of HDGF knockdown on the migration and invasiveness of DU145 and PC3 cells. \*P \< 0.05 compared with the si-NC-transfected cells.

HDGF Overexpression Neutralizes the Antitumor Activity of miR-939 in PCa Cells {#S0003-S2006}
------------------------------------------------------------------------------

Rescue experiments were conducted to further confirm that HDGF downregulation is essential for the anticancer activity of miR-939 overexpression in PCa tumorigenesis. To this end, we restored HDGF expression in agomir-939-transfected DU145 and PC3 cells by cotransfecting these cells with the HDGF-overexpressing plasmid pc-HDGF ([Figure 6A](#F0006){ref-type="fig"}, P \< 0.05). We found that the recovery of HDGF expression countered the effects of miR-939 upregulation on the proliferation ([Figure 6B](#F0006){ref-type="fig"}, P \< 0.05), colony formation ([Figure 6C](#F0006){ref-type="fig"}, P \< 0.05), apoptosis ([Figure 6D](#F0006){ref-type="fig"}, P \< 0.05), migration ([Figure 6E](#F0006){ref-type="fig"}, P \< 0.05), and invasiveness ([Figure 6F](#F0006){ref-type="fig"}, P \< 0.05) of DU145 and PC3 cells. These results strongly indicated that HDGF is functionally involved in the miR‐939-mediated suppression of PCa aggressiveness.Figure 6Recovery of HDGF expression counteracts the tumor-suppressive effect of miR-939 overexpression in DU145 and PC3 cells. (**A**) Either the HDGF-overexpressing plasmid pc-HDGF or empty pcDNA3.1 vector was introduced into DU145 and PC3 cells in the presence of agomir-939. Transfection of pc-HDGF restored HDGF expression in miR-939-overexpressing DU145 and PC3 cells, as revealed by Western blotting. \*P \< 0.05 compared with the agomir-NC-transfected cells. ^\#^P \< 0.05 compared with the agomir-939+pcDNA3.1 -transfected cells. (**B--F**) The proliferation, colony formation, apoptosis, migration, and invasiveness of the aforementioned cells were tested by the CCK-8 assay, colony formation assay, flow cytometry, and transwell assays. \*P \< 0.05 compared with the agomir-NC group. ^\#^P \< 0.05 compared with the agomir-939+pcDNA3.1 group.

miR-939 Overexpression Deactivates the WNT/β-Catenin Pathway in PCa by Downregulating HDGF {#S0003-S2007}
------------------------------------------------------------------------------------------

Previous studies have reported the involvement of HDGF in the regulation of the WNT/β-catenin pathway.[@CIT0032]--[@CIT0034] Accordingly, we tested whether miR-939 affects WNT/β-catenin signaling in PCa. To this end, we conducted Western blotting to quantify the important molecules associated with the WNT/β-catenin pathway in DU145 and PC3 cells transfected with agomir-939 in the presence of either pc-HDGF or pcDNA3.1. The levels of p-β-catenin and cyclin D1 levels were significantly lower in the agomir-939-transfected cells than in the agomir-NC-transfected cells, whereas total β-catenin expression was unaffected by miR-939 overexpression. Of note, the miR-939 overexpression-mediated decrease in p-β-catenin and cyclin D1 protein expression was reversed in DU145 and PC3 cells after cotransfection with the HDGF-overexpressing plasmid pc-HDGF ([Figure 7](#F0007){ref-type="fig"}). These results clearly showed that miR-939 inhibited the activation of the WNT/β-catenin pathway in PCa cells by decreasing HDGF expression.Figure 7MiR-939 upregulation suppresses HDGF expression and inhibits activation of the WNT/β-catenin pathway in PCa. Agomir-939 along with either pc-HDGF or pcDNA3.1 was transfected into DU145 and PC3 cells. At 72 h posttransfection, the expression levels of p-β-catenin, cyclin D1, and β-catenin were measured by Western blotting.

miR-939 Overexpression Impairs Tumor Growth of PCa Cells in vivo {#S0003-S2008}
----------------------------------------------------------------

The effect of miR-939 overexpression on the tumor growth of PCa cells in vivo was determined in the tumor xenograft model. DU145 cells were transfected with either agomir-939 or agomir-NC and then inoculated into nude mice to generate a PCa xenograft model. The nude mice injected with miR-939-overexpressing DU145 cells developed remarkably smaller tumor xenografts that exhibited delayed tumor growth ([Figure 8A](#F0008){ref-type="fig"} and [B](#F0008){ref-type="fig"}, P \< 0.05). The tumor xenograft weight was significantly lower in the agomir-939-transfected cells than that in the agomir-NC-transfected cells ([Figure 8C](#F0008){ref-type="fig"}, P \< 0.05). The successful overexpression of miR-939 was confirmed in the tumor xenografts derived from agomir-939-transfected DU145 cells ([Figure 8D](#F0008){ref-type="fig"}, P \< 0.05). Western blotting was also performed to determine the expression of HDGF and the components of the WNT/β-catenin pathway in the tumor xenografts. The results revealed that the protein levels of HDGF, p-β-catenin, and cyclin D1 were significantly lower in the agomir-939-transfected cells than in the agomir-NC-transfected cells ([Figure 8E](#F0008){ref-type="fig"}). Taken together, our findings suggested that miR-939 overexpression inhibits the tumor growth of PCa cells in vivo by downregulating HDGF and deactivating the WNT/β-catenin pathway.Figure 8miR-939 overexpression inhibits tumor growth in vivo. (**A**) DU145 cells transfected with either agomir-939 or agomir-NC were subcutaneously inoculated into nude mice. Images of the tumor xenografts at the end of the experiment are shown. (**B**) The growth curves were plotted to monitor the volume of tumor xenografts for 4 weeks. \*P \< 0.05 compared with the agomir-NC-transfected cells. (**C**) Measurement of tumor xenografts was conducted at the end of the experiment. \*P \< 0.05 compared with the agomir-NC-transfected cells. (**D**) Expression of miR-939 in mouse tumor xenografts transfected with agomir-939 or agomir-NC was analyzed by RT--qPCR. \*P \< 0.05 compared with agomir-NC-transfected cells. (**E**) Changes in the expression levels of HDGF, p-β-catenin, cyclin D1, and β-catenin in nude mice after miR-939 overexpression were determined via Western blotting.

Discussion {#S0004}
==========

Changes in the expression of miRNAs in PCa cells have been frequently reported.[@CIT0035]--[@CIT0037] These abnormally expressed miRNAs may function as key mediators of prostate carcinogenesis and PCa progression by influencing various biological processes.[@CIT0038]--[@CIT0040] Therefore, a comprehensive understanding of PCa pathogenesis may improve the diagnosis, prognosis, and treatment of this disease. The present study aimed to determine miR-939 expression in PCa cells and explore its clinical value among patients with PCa. In particular, this study explored the functional roles of miR-939 in PCa progression and the underlying molecular mechanisms.

The expression profile of miR-939 has been well studied in several types of human cancer. For instance, it has been reported that miR-939 is downregulated in tongue squamous cell carcinoma and this downregulation is negatively correlated with tumor stage.[@CIT0041] Low miR-939 expression has also been reported in gastric[@CIT0030] and colorectal[@CIT0029] cancers. This low miR-939 expression is known to be a biomarker for poor prognosis and recurrence in patients with gastric cancer.[@CIT0030] Conversely, miR-939 overexpression has been reported in hepatocellular carcinoma[@CIT0042] and ovarian cancer.[@CIT0031] These conflicting observations increased our interest in determining the expression profile of miR-939 in PCa. The results of the present study revealed that miR-939 was expressed at markedly low levels in PCa tissues and cell lines. Furthermore, clinical analysis showed that this low miR-939 expression was clearly associated with tumor stage and lymphatic metastasis. In addition, patients with PCa exhibiting low miR-939 expression showed poorer prognosis than those exhibiting high miR-939 expression. These results suggested miR-939 as a valuable diagnostic and prognostic indicator of PCa.

The role of miR-939 in tumorigenesis and tumor development has been explored in detail in the literature. For example, restoration of miR-939 expression attenuates the migratory and invasive abilities of colorectal cancer cells by directly targeting LIM domain kinase 2.[@CIT0029] In addition, restored miR-939 expression restricts gastric cancer cell proliferation, migration, and invasion in vitro; increases 5-fluorouracil-induced chemosensitivity; and inhibits lung metastasis in vivo.[@CIT0030] These effects were found to be mediated by a decrease in SLC34A2 expression and deactivation of the RAF/MEK/ERK pathway.[@CIT0030] However, a contradictory function of miR-939 has been observed in ovarian cancer. Ectopic miR-939 expression increases ovarian cancer cell proliferation and anchorage-independent growth by inhibiting the APC2/WNT/β-catenin pathway.[@CIT0031] However, the detailed roles of miR-939 in PCa progression remain elusive. Herein, we found that miR-939 exerted a tumor-suppressive effect on PCa cells by suppressing cell growth and metastasis in vitro and inhibiting tumor growth in vivo.

Detailed investigation of the molecular mechanisms regulating the tumor-suppressive effects of miR-939 on PCa is important to discover novel therapeutic targets and improve the prognosis of patients with PCa. In the present study, *HDGF* was confirmed as a direct and functional target of miR-939 in PCa. *HDGF*, located on chromosome 1 region q21--q23, is upregulated in several types of human cancer, including PCa,[@CIT0043],[@CIT0044] endometrial cancer,[@CIT0045] hepatocellular carcinoma,[@CIT0046] ovarian cancer,[@CIT0047] gastric cancer,[@CIT0048] and glioma.[@CIT0049] *HDGF* serves as an oncogene in the malignant progression of PCa and is implicated in the regulation of cell proliferation, survival, migration, and invasion.[@CIT0043],[@CIT0044] The results of the present study confirmed the oncogenic role of HDGF in PCa progression. Moreover, miR-939 was found to directly target *HDGF* mRNA to suppress PCa progression via deactivation of the WNT/β-catenin pathway. Accordingly, miR-939 upregulation, which results in HDGF inhibition and WNT/β-catenin pathway deactivation, may be a promising therapeutic strategy for patients with PCa.

Conclusion {#S0005}
==========

The present study characterized the antitumorigenic roles of miR-939 in attenuating the oncogenicity of PCa in vitro and in vivo. In terms of the mechanism, the tumor-suppressive effect of miR-939 on PCa cells is suggested to be mediated by inhibition of the HDGF/WNT/β-catenin pathway. Our study findings regarding miR-939, its direct target gene *HDGF*, and the WNT/β-catenin pathway involved in PCa may help in identifying novel targets for anticancer therapy.
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